The maker of EpiPens offered patients more help to pay for its costly emergency allergy shots but didn't budge Thursday on the $608 price.
The announcement from Mylan N.V. triggered a new round of condemnation from politicians and consumer groups, who accuse the company of price-gouging on a potentially life-saving treatment.
Critics stressed that insurers, employers and taxpayers will still foot most of the cost for EpiPens. Over time, that drives up insurance premiums and the country's burgeoning health care tab.
"Everybody suffers, except the Mylan investors," said Sabrina Corlette of Georgetown University's Health Policy Institute.